Abstract 5805
Background
Due to their intrinsic thermal and magnetic resonance imaging properties, magnetic nanoparticles (MNCs) have attracted more and more attention in the biomedical field. However, relatively weak photothermal conversion (PTC) efficiency and low tumor homing capacity has hampered its further application in vivo.
Methods
To solve these problems, we modified near-infrared (NIR) light-absorbing materials onto the surface of MNCs to increase PTC efficiency and increase MNCs tumor homing capacity by coated red blood cell (RBC) membranes.
Results
Our data show that after being loaded with NIR cypate molecules, the as-prepared Cyp-MNCs showed remarkably increased NIR absorbance and resultant PTC efficiency compared with the MNCs. By disguising itself, Cyp-MNCs coated with erythrocyte membranes inherit the long circulation characteristics of RBCs to improve the MNCs’ tumor homing capacity. By tracking the NIR fluorescence of cypate under an in vivo fluorescence imaging system, we discovered that such Cyp-MNC@RBCs upon intravenous injection show significantly improved tumor homing capacity compared with bare cypate-loaded MNCs. The antitumor efficiency of biomimetic Cyp-MNC@RBCs was particularly prominent and was superior to biomimetic MNC@RBCs. Additionally, fluorescence and T2-weighted magnetic resonance imaging (MRI) functionalities were all retained attributable to Cyp-MNC@RBCs cores.
Conclusions
Our study would provide a promising procedure for other similarly enhanced photothermal treatments by increasing PTC efficincies and improving tumor-homing capacity.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5437 - Salivary cytokines and oral mucosa cells apoptosis in patients during hematopoietic cell transplantation: possible relationship with oral mucositis
Presenter: Luciana Corrêa
Session: Poster Display session 1
Resources:
Abstract
1483 - A randomized trial of sodium alginate prevention of radiation-induced esophagitis in patients with locally advanced NSCLC receiving concurrent chemoradiotherapy: OLCSG1401
Presenter: Toshihide Yokoyama
Session: Poster Display session 1
Resources:
Abstract
2047 - Taste and smell alterations (TSAs) in patients (pts) with stage II-III colon cancer (CC): a pilot within the PROTECT study
Presenter: Jeroen Derksen
Session: Poster Display session 1
Resources:
Abstract
5984 - Clinical characteristics are associated with acupuncture treatment response for xerostomia in cancer patients
Presenter: Wenli Liu
Session: Poster Display session 1
Resources:
Abstract
2845 - Psychosocial Distress of Adolescent and Young Adults with Cancer at Diagnosis: A Case-Matched Retrospective Cohort of 2045 Patients in British Columbia.
Presenter: Alannah Smrke
Session: Poster Display session 1
Resources:
Abstract
724 - Accuracy of distress thermometer to measure cancer-related mood disorders in Chinese patients with cancer
Presenter: Sudip Thapa
Session: Poster Display session 1
Resources:
Abstract
2357 - Modalities of biosimilar filgrastim use in clinical practice in >1000 patients receiving chemotherapy regimens with a rest period of ≤14 days: the TOPAZE study
Presenter: Jean Marc Phelip
Session: Poster Display session 1
Resources:
Abstract
1426 - The Effect of Increasing Doses of Pegfilgrastim (Peg) on Thrombocytopenia (T) in Breast Cancer (BC) Patients (pts) Receiving Taxotere (Doc), Doxorubicin, Cyclophosphamide (TAC) and Plinabulin (Plin)
Presenter: Douglas Blayney
Session: Poster Display session 1
Resources:
Abstract
712 - The use of intravenous ferric carboxymaltose without erythropoiesis-stimulating agents in the treatment of anemia in cancer patients undergoing chemotherapy with or without radiotherapy
Presenter: Hikmat Abdel-Razeq
Session: Poster Display session 1
Resources:
Abstract
1496 - Randomized, double-blind, cross-over Phase I study comparing pharmacokinetics, pharmacodynamics, safety and immunogenicity of a biosimilar pegfilgrastim with EU and US references
Presenter: Maria Velinova
Session: Poster Display session 1
Resources:
Abstract